COLLABORATIVE TRAINING HUB
The Collaborative Training Hub is an open access launchpad to quickly access unique clinical trials training resources and opportunities. These curated mini-series offer you access to high-quality learning material produced by CANTRAIN or by other Canadian leaders in the clinical trial landscape. All training is available on-demand via computer, tablet, and phone, and does not require registration or login.
Do you have a training offering or resource that could be hosted on our Collaborative Training Hub? Ideas for content or potential Collaborative Training Hub partnerships? We would love to hear from you: communication@wecantrain.ca
CBITN
DISCLAIMER: Captions are automatically generated and may not be fully accurate
Towards an integrated framework for designing and testing behaviour change interventions
Prof. Simon L. Bacon, Concordia University (Canada)
________
This modules focuses on some of the major limitations in current behavioural intervention studies, explores the process of generating and testing a behavioural intervention as well as some key questions to ask of behavioural intervention studies.
46 min
Required pre-readings
Designing Effective Health Behaviour Change Interventions: Using the Behaviour Change Wheel and Beyond
Asst. Prof. Marta Marques, NOVA University of Lisbon (Portugal)
________
This modules focuses on behaviour change techniques and on differentiating frameworks, models and classification systems applicable to behaviour change interventions, explores the Behaviour Change Wheel framework and the COM-B Model of Behaviour Change, and discusses the importance of specifying and classifying components of behaviour change interventions during their development.
47 min
Required pre-readings
A Review and Comparison of Behavioral Intervention Development Frameworks: The ORBIT Model, The Science of Behavior Change (SOBC) approach, and the MRC framework
Susan M. Czajkowski, Chief of the Health Behaviors Research Branch – Division of Cancer Control and Population Sciences, National Cancer Institute (USA)
________
This module focuses on the goals and purposes of three behavioral intervention development and testing approaches, explore the key features and relationships between each of these frameworks, and also explore how best to select frameworks for the development of specific interventions.
50 min
Required pre-readings
Clinical Behavioural Trial Designs (e.g, adaptive/SMART, Pragmatic, n of 1, etc)
Assoc. Prof. Sylvie Lambert, McGill University (Canada)
________
This module focuses on evaluating behavioural interventions through different trial designs, exploring alternative trial designs used to evaluate components of a behavioral intervention and overviewing the strengths and weaknesses of each of the explored trial designs.
59 min
Required pre-readings
Outcome selection in behavioural trials: Challenges and opportunities
Prof. Kim Lavoie, Université du Québec à Montréal (Canada)
________
This module focuses on different types of trial outcomes and their purposes, the unique challenges associated with selecting outcomes for behavioural trials, and defining the benefits of core outcome sets to improve outcome selection and reporting in behavioural trials.
29 min
Required pre-readings
Optimizing Behavioral Interventions: Introduction to MOST
Asst. Prof. Kate Guastaferro, New York University School of Global Public Health (USA)
________
This module focuses on the rationale for, and process of, intervention optimization via the Multiphase Optimization Strategy (MOST) and Intervention EASE approaches and making contrasts with the classical treatment package approach.
44 min
Required pre-readings
Feasibility and Pilot (F+P) Testing
Prof. Simon Bacon, Concordia University (Canada)
________
This module focuses on distinguishing between feasibility and pilot studies and exploring the knowledge gaps around these types of studies as well as reporting in relation to these two types of studies.
54 min
Required pre-readings
Assessments in Behavioural Trials: Treatment Fidelity
Prof. Kim Lavoie, Université du Québec à Montréal (Canada)
________
This modules focuses on the importance of addressing intervention fidelity within behavioural trials, understanding fidelity and its relation to adaptation, and identifying appropriate fidelity assessment strategies.
38 min
Required pre-readings
Knowledge user engagement & designing for implementation
Prof. Molly Byrne, University of Galway, Ireland (Ireland)
________
This module focuses on engaging relevant stakeholders to maximise intervention relevance, fidelity, effectiveness, and implementation; identifying implementation barriers and enablers and selecting fit-for-purpose implementation and evaluation frameworks, strategies and techniques.
38 min
Required pre-readings
Implementation Science Theories and Frameworks to Improve Translation of Research to Practice
Assoc. Prof. Justin Presseau, University of Ottawa (Canada)
________
This model focuses on implementation science, emphasizing its theories and frameworks designed to enhance the application of research findings into practical use. It outlines the differences between frameworks that help identify barriers and facilitators to implementation and those that aid in selecting effective implementation strategies.
53 min
Required pre-readings
Ika Washington, MSc., BSc, Ph.D. Student
Critical Health Sociologist, Public Health Practitioner, Patient, and Founder of Diversity Talk
2024 NATIONAL CLINICAL TRIAL TRAINING SUMMIT
DISCLAIMER: Each video of the series is in English. Automatically generated subtitles in both French and English are available but may not be fully accurate.
This 18-part mini-series by CANTRAIN compiles for you the full-length sessions from our 2024 Clinical Trials Training Summit, held in Montréal in February 2024. This mini-series covers a variety of topics from strategies to make clinical trials more patient centric, to discussing the benefits of incorporating a behavioural science perspective in clinical trials, and hearing first-hand the experience of developing and implementing a comprehensive clinical trials competency framework. Watch or rewatch these sessions that give you key updates and insights from experts across the clinical trials landscape.
# | Presenter | Title | Duration |
---|---|---|---|
01 | Pr. Linda Li, BSc(PT), PhD, FCAHS | Bright Future: Training Tomorrow’s Leaders in Patient Research Partnerships | 35 min |
02 | Ika Washington, MSc, BSc, PhD Student | Marginalization and Equity in Research | 30 min |
03 | Dr. Natalie Coburn, MD, MPH | How We Can Make Clinical Trials More Patient Centric | 41 min |
04a | André Pierre Picard, OC | The Future of Clinical Trials: Patient and Community Partners Perspectives | 31 min |
04b | André Picard, OC Dr. Linda Hunter, RN MScN, PhD(C) Alex Haagaard, BSc, MDes Dr. Natalie Coburn, MD, MPH Ika Washington, MSc., BSc, Ph.D. Student Jeniffer EJ Monaghan, BA, LLB Maureen Smith, MEd Saeideh Mayanloo, BSc Shurjeel Choudhri, BSc(med), MD, FRCPC | Panel Discussion | 69 min |
05 | Pr. Barbara Bierer, BSc, MD | From Theory to Practice: Development and Implementation of the JTF: Joint Task Force for Clinical Trials Competency Framework | 33 min |
06 | Dr. Sandra Pelaez, BEdPsy, MSc, PhD Christina Farant Monique Ostrout, BSc, DESS Katie Bainbridge, BA, MIS Dr. Linda Hunter, RN MScN, PhD(C) Mei Li, BN, MHM, PhD(C) Caroline Buote, BSc, MSc Dan Lafreniere, BSc | From the Grant to the Field: Challenges of Developing an Innovative Curriculum for Clinical Trials | 73 min |
07 | Munaza Jamil, BSC, CCRA | Crafting a Common Language: Standardized Role Profiles for Clinical Research Professionals in Canada | 24 min |
10 | Dr. Andrea Furlan, MD, PhD | De-Monopolizing Knowledge in Communities of Practice With Case-Based Learning: All Teach, All Learn | 21 min |
11 | Dr. Suzanne Morin, MD, MSc, FRCP, FACP Damaris Javier, MA Dr. Lisa Goos, BScH, BEd, MA, PhD | Supporting Accessibility, Diversity and Equity in Mentorship Program | 28 min |
12 | Dr Kieran Quinn, MD, PhD | Pragmatic Lessons in the Design of Advanced Clinical Trials | 34 min |
13 | Anna Heath, MMath, PhD | The Art of Biostatistics in Clinical Trials | 39 min |
14 | Dr. Lauren Kelly, MSc, PhD, CCRP | Increasing Capacity of Maternal and Paediatric Clinical Trials in Canada | 41 min |
15 | Pr. Kim Lavoie, PhD, FCPA, FABMR | Why All Trials are Behavioural Trials - Opening Remarks | 13 min |
16 | Pr. Simon Bacon, PhD, FTOS, FCCS, FABMR | Towards an Integrated Framework for designing and Testing Interventions Targeting Physical Activity, Diet, and Other Health Risk Behaviours: Why Some of the Major Trials Have 'Failed' and How We Can Do Better | 39 min |
17 | Pr. Genevieve Rouleau, MSc, PhD | Why Should We Care About Implementation Science in Health-Related Research | 29 min |
18 | Pr. Michael Vallis, PhD, R.Psych | How clinical trials Can Benefit From Incorporating a Behavioural Science Perspective: Challenges and Opportunities | 52 min |
Panel Discussion
André Picard, OC (Moderator) | Reporter Health columnist, The Globe and Mail |
Dr. Linda Hunter, RN MScN, PhD(C) (Chair) | National Coordinator Trialists Stream, CANTRAIN |
PANELISTS | |
Dr. Linda Hunter, RN MScN, PhD(C) (Chair) | National Coordinator Trialists Stream, CANTRAIN |
Alex Haagaard, BSc, MDes | Equity-Centered Design Strategist Patient Partner, Pain BC, Co-Chair, Knowledge Mobilization and Implementation Science Committee, Chronic Pain Network |
Dr. Natalie Coburn, MD, MPH | Senior scientist Sunnybrook Research Institute; Professor at University of Toronto |
Ika Washington, MSc, BSc, PhD Student | Critical Health Sociologist Public Health Practitioner, Patient, and Founder of DiversityTalk |
Jeniffer EJ Monaghan, BA, LLB | Patient Partner STROKECOG Executive Committee |
Maureen Smith, MEd | Patient Partner Adjunct Professor, University of Toronto Dalla Lana School of Public Health, ACT Consortium, Patient Engagement & Training Committees member, Co-lead INFORM RARE Patient Engagement, IMPaCT Parent/Youth Engagement Lead |
Saeideh Mayanloo, BSc | Site Engagement Lead AstraZeneca |
Shurjeel Choudhri, BSc(med), MD, FRCPC | SVP and Head Medical & Scientific Affairs, Pharmaceuticals, Bayer Inc |
69 min
From Theory to Practice: Development and Implementation of the JTF: Joint Task Force for Clinical Trials Competency Framework
Barbara Bierer, BSc, MD
Faculty Director, Multi- Regional Clinical Trials Center of Brigham and Women’s Hospital and Harvard University; Director, Regulatory Foundations, Ethics and Law Program, Harvard Clinical and Translational Science Center Director, SMART IRB
33 min
From the Grant to the Field: Challenges of Developing an Innovative Curriculum for Clinical Trials
Dr. Sandra Pelaez, BEdPsy., MSc, PhD | National Director Clinical Trials Training Programs’ Streams, CANTRAIN |
Christina Farant | National Coordinator Graduate & Postdoctoral Trainee Stream, CANTRAIN |
Monique Ostrout, BSc, DESS | National Coordinator Clinical Research Professionals Stream, CANTRAIN |
Katie Bainbridge, BA, MIS | National Coordinator Trialists Stream, CANTRAIN |
Dr. Linda Hunter, RN MScN, PhD(C) | National Coordinator Trialists Stream, CANTRAIN |
Mei Li, BN, MHM, PhD(C) | Team Leader Clinical Research Educator, CANTRAIN |
Caroline Buote, BSc, MSc | Team Leader Program Designer & Developer, CANTRAIN |
Dan Lafreniere, BSc | Clinical Research Educator CANTRAIN |
73 min
Towards an Integrated Framework for Designing and Testing Interventions Targeting Physical Activity, Diet, and Other Health Risk Behaviours: Why Some of the Major Trials Have 'Failed' and How We Can Do Better
Simon Bacon, PhD, FTOS, FCCS, FABMR
Professor and CIHR SPOR Chair in Innovative, Patient-Oriented, Behavioural Clinical Trials, Health, Kinesiology and Applied Physiology
39 min
Pragmatic Trials Training Program
This 9-part mini-series, provided to you in collaboration with Health Data Research Network Canada (HDRN Canada) Pragmatic Trials Training Program serves as an introduction to HDRN Canada’s Pragmatic Trials Training Program – a pan-Canadian initiative that offers weekly open-access modules on all aspects of pragmatic trials, from design & implementation to statistical analysis, quality control and other trial components. The distinctive feature of the pragmatic trials approach is that it aims to maximize efficiency by enrolling all participants with a condition of interest, having healthcare staff deliver the intervention (as opposed to research staff), and harnessing efficient data collection strategies that leverage existing pools of health and health related data, such as that available through networks such as HDRN Canada. Dive into this mini-series to wrap your head around the specifics of this innovative approach.
# | Presenter | Title | Duration |
---|---|---|---|
1 | Prof. Amit X. Garg | Welcome - Program Lead | 4 min |
2 | Dr. Taylor McLinden | Program Overview | 6 min |
3a | Prof. Amit X. Garg | Exemplar Trial Intro - EnAKT LKD | 2 min |
3b | Prof. Amit X. Garg, et al. | Exemplar Trial Overview - EnAKT LKD | 13 min |
3c | Prof. Amit X. Garg, et al. | Exemplar Trial Overview - AToM (Ambulatory Toxicity Management) | 13 min |
4a | Prof. Monica Kryyzanowska | Exemplar Trial - AToM | 14 min |
4b | Prof. Monica Kryyzanowska & Ass.Prof. Melanie Powis | Exemplar Trial - AToM | 14 min |
5a | Prof. Noah M. Ivers | Exemplar Trial - ISLAND | 15 min |
5b | Prof. Noah M. Ivers | Exemplar Trial Overview - ISLAND | 10 min |
DISCLAIMER: Each video of the series is in English. Automatically generated subtitles are available but may not be fully accurate.
Exemplar Trial Overview - EnAKT LKD
Professor Amit X. Garg, et al.
MD, PhD
Overviews EnAKT LKD, a pragmatic, 2-arm, parallel-group, open-label, registry-based, superiority, cluster randomized clinical trial to evaluate the effect of a multicomponent intervention designed to target several barriers that prevent eligible patients from completing key steps towards receiving a kidney transplant.
13 min
Exemplar Trial Overview- AToM (Ambulatory Toxicity Management)
Professor Monica Kryyzanowska
MD, MPH, FRCPC, FASCO